You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Diets Articles
Popular Diets Articles
Highly Recommended Diets Articles
Send a link to this page to your friends and colleagues.
Orexigen Therapeutics has announced that the investigational weight loss drug Contrave (naltrexone SR/bupropion SR) reduced the prevalence of metabolic syndrome, which is associated with an increased risk of diabetes and heart disease, by 50 percent.
Contrave is a weight loss medication that works in two places in the central nervous system. It works in the hypothalmus which controls the balance of food intake and metabolism. Contrave also works to address a second site, the reward system in the brain that controls food preference and food cravings.
According to a press release from the recent annual Obesity Society Scientific Meeting in Phoenix, Arizona, in clinical trials, Contrave showed a significant weight loss over one year of treatment (approximately 8% to 10.7% in patients completing 48 weeks of therapy) by reducing appetite, increasing metabolism, and by changing the body's natural tendency to slow down the weight loss process. The developers expect to receive data from the first Contrave Phase 3 trials in January of 2009 and the remaining three trials by mid-next year.
Contrave is currently in Phase 3 clinical trials and in line for a late 2009 New Drug Application (NDA) submission to the FDA.
Further information can be found at Orexigen.com.
Source: The Obesity Society
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.